These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
535 related articles for article (PubMed ID: 7679609)
21. Characterization of effector-target conjugates for cloned human natural killer and human lymphokine activated killer cells by flow cytometry. Callewaert DM; Radcliff G; Waite R; LeFevre J; Poulik MD Cytometry; 1991; 12(7):666-76. PubMed ID: 1782834 [TBL] [Abstract][Full Text] [Related]
22. Leukoregulin up-regulation of tumor cell sensitivity to natural killer and lymphokine-activated killer cell cytotoxicity. Furbert-Harris PM; Evans CH Cancer Immunol Immunother; 1989; 30(2):86-91. PubMed ID: 2688871 [TBL] [Abstract][Full Text] [Related]
23. Interferon gamma enhances lymphokine-activated killer cell adhesion but not lysis of head and neck squamous cell carcinoma. Scher RL; Carras A; Schwab D; Richtsmeier WJ; Koch WM Arch Otolaryngol Head Neck Surg; 1995 Nov; 121(11):1271-5. PubMed ID: 7576474 [TBL] [Abstract][Full Text] [Related]
24. Cytotoxicity of interleukin 2-induced lymphokine-activated killer (LAK) cells against human leukemia and augmentation of killing by interferons and tumor necrosis factor. Teichmann JV; Ludwig WD; Thiel E Leuk Res; 1992; 16(3):287-98. PubMed ID: 1560676 [TBL] [Abstract][Full Text] [Related]
25. The lack of NK cytotoxicity associated with fresh HUCB may be due to the presence of soluble HLA in the serum. Webb BJ; Bochan MR; Montel A; Padilla LM; Brahmi Z Cell Immunol; 1994 Dec; 159(2):246-61. PubMed ID: 7994757 [TBL] [Abstract][Full Text] [Related]
26. Lysis of human malignant mesothelioma cells by natural killer (NK) and lymphokine-activated killer (LAK) cells. Manning LS; Bowman RV; Darby SB; Robinson BW Am Rev Respir Dis; 1989 Jun; 139(6):1369-74. PubMed ID: 2786360 [TBL] [Abstract][Full Text] [Related]
27. Studies on the mechanism of natural killer cell-mediated cytotoxicity. IV. Interferon-induced inhibition of NK target cell susceptibility to lysis is due to a defect in their ability to stimulate release of natural killer cytotoxic factors (NKCF). Wright SC; Bonavida B J Immunol; 1983 Jun; 130(6):2965-8. PubMed ID: 6189909 [TBL] [Abstract][Full Text] [Related]
28. Enhancement of natural killer cytotoxicity by cis-diamminedichloroplatinum (II) in vivo and in vitro. Lichtenstein AK; Pende D Cancer Res; 1986 Feb; 46(2):639-44. PubMed ID: 3940633 [TBL] [Abstract][Full Text] [Related]
29. LAK-cell-mediated cytotoxicity against tumor cell targets used to monitor the stimulatory effect of interleukin-2: cytotoxicity, target recognition and phenotype of effector cells lysing the Daudi, T24 and K562 tumor cell lines. Hermann GG; Zeuthen J; Claësson MH Nat Immun; 1992; 11(1):7-16. PubMed ID: 1611282 [TBL] [Abstract][Full Text] [Related]
30. The streptococcal preparation OK-432 specifically augments the susceptibility of human urinary bladder tumor cells to autologous peripheral blood lymphocytes. Mizutani Y; Nio Y; Yoshida O Cancer; 1992 Jun; 69(12):2999-3007. PubMed ID: 1591693 [TBL] [Abstract][Full Text] [Related]
31. Interferon-gamma induces a decrease in the susceptibility of human glioma cells to lysis by lymphokine-activated killer cells. Yin D; Kondo S; Takeuchi J; Morimura T; Nakatsu S; Oda Y; Kikuchi H Neurosurgery; 1994 Jul; 35(1):113-8. PubMed ID: 7936131 [TBL] [Abstract][Full Text] [Related]
32. Natural killer and lymphokine-activated killer activities in stomach cancer patients with special emphasis on the effect of 5-fluorouracil, adriamycin and mitomycin-C chemotherapy. Hong WS; Kim CM; Lee JO; Kang TW; Yun TK; Kim CY Jpn J Clin Oncol; 1990 Mar; 20(1):87-93. PubMed ID: 2108272 [TBL] [Abstract][Full Text] [Related]
33. Induction of lymphokine-activated killer activity by interleukin 4 in human lymphocytes preactivated by interleukin 2 in vivo or in vitro. Higuchi CM; Thompson JA; Lindgren CG; Gillis S; Widmer MB; Kern DE; Fefer A Cancer Res; 1989 Dec; 49(23):6487-92. PubMed ID: 2479463 [TBL] [Abstract][Full Text] [Related]
34. Mechanism of interferon gamma-induced protection of human gliosarcoma cells from lymphokine-activated killer lysis: division of lymphokine-activated killer cells into natural killer- and T-like cells. Kondo S; Miyatake S; Kikuchi H; Oda Y; Iwasaki K; Ohyama K; Namba Y Neurosurgery; 1992 Sep; 31(3):534-40. PubMed ID: 1407434 [TBL] [Abstract][Full Text] [Related]
35. Modulation of leukemic cell sensitivity to lymphokine-activated killer cytolysis: role of intercellular adhesion molecule-1. Triozzi PL; Eicher DM; Smoot J; Rinehart JJ Exp Hematol; 1992 Oct; 20(9):1072-6. PubMed ID: 1361453 [TBL] [Abstract][Full Text] [Related]
36. Natural killer cells in children with malignant solid tumors. Effect of recombinant interferon-alpha and interleukin-2 on natural killer cell function against tumor cell lines. Alvarado CS; Findley HW; Chan WC; Hnath RS; Abdel-Mageed A; Pais RC; Kutner MH; Ragab AH Cancer; 1989 Jan; 63(1):83-9. PubMed ID: 2783377 [TBL] [Abstract][Full Text] [Related]
37. Studies on the susceptibility to NK-mediated lysis and the simultaneous expression of various surface molecules in anthracyclin-treated K562 cells and in four K562 cell clones. Benoist H; Joly P; Broglio C; Jeannesson P; Idoine O; Dufer J; Desplaces A Immunol Lett; 1992 Sep; 34(1):45-55. PubMed ID: 1362185 [TBL] [Abstract][Full Text] [Related]
38. Interferon is able to reduce tumor cell susceptibility to human lymphokine-activated killer (LAK) cells. Grönberg A; Ferm M; Tsai L; Kiessling R Cell Immunol; 1989 Jan; 118(1):10-21. PubMed ID: 2463094 [TBL] [Abstract][Full Text] [Related]
39. Cellular cytotoxicity of human natural killer cells and lymphokine-activated killer cells against bladder carcinoma cell lines. Wang MH; Flad HD; Böhle A; Chen YQ; Ulmer AJ Immunol Lett; 1991 Mar; 27(3):191-7. PubMed ID: 2060970 [TBL] [Abstract][Full Text] [Related]
40. IFN-gamma treatment of K562 cells inhibits natural killer cell triggering and decreases the susceptibility to lysis by cytoplasmic granules from large granular lymphocytes. Grönberg A; Ferm MT; Ng J; Reynolds CW; Ortaldo JR J Immunol; 1988 Jun; 140(12):4397-402. PubMed ID: 3131433 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]